Jazz Pharmaceuticals
E874302
Jazz Pharmaceuticals is a biopharmaceutical company specializing in developing and commercializing innovative medicines for sleep disorders, oncology, and rare diseases.
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
biopharmaceutical company
ⓘ
public company ⓘ |
| acquired | GW Pharmaceuticals NERFINISHED ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| engagesIn |
clinical research
ⓘ
commercialization of therapies ⓘ drug development ⓘ |
| focusesOn |
oncology
ⓘ
rare diseases ⓘ sleep disorders ⓘ unmet medical needs ⓘ |
| foundedAs | Jazz Pharmaceuticals, Inc. NERFINISHED ⓘ |
| hasKeyProductType |
orphan drugs
ⓘ
specialty pharmaceuticals ⓘ |
| hasProduct |
Defitelio
NERFINISHED
ⓘ
Epidiolex NERFINISHED ⓘ Rylaze NERFINISHED ⓘ Sunosi NERFINISHED ⓘ Vyxeos NERFINISHED ⓘ Xyrem NERFINISHED ⓘ Xywav NERFINISHED ⓘ Zepzelca NERFINISHED ⓘ |
| hasSubsidiary | GW Pharmaceuticals NERFINISHED ⓘ |
| hasTherapeuticArea |
hematology
ⓘ
oncology ⓘ rare diseases ⓘ sleep medicine ⓘ |
| hasTickerSymbol | JAZZ NERFINISHED ⓘ |
| headquartersCountry | Ireland NERFINISHED ⓘ |
| headquartersLocation | Dublin NERFINISHED ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| listedOn | NASDAQ ⓘ |
| regulatoryApprovalFrom |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| specializesIn |
commercializing medicines
ⓘ
developing medicines ⓘ |
| targetMarket | patients with serious diseases ⓘ |
| treatsCondition |
Dravet syndrome
NERFINISHED
ⓘ
Lennox–Gastaut syndrome NERFINISHED ⓘ acute lymphoblastic leukemia ⓘ acute myeloid leukemia ⓘ cataplexy ⓘ excessive daytime sleepiness ⓘ hepatic veno-occlusive disease ⓘ narcolepsy ⓘ small cell lung cancer ⓘ tuberous sclerosis complex–associated seizures ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.